BD DIAGNOSTIC SYSTEMS and BD GENEOHM are leading providers in the field of healthcare-associated infection testing. With the company’s CE-marked rapid molecular PCR-based screening tests, carriers of infections can be identified within two hours.
This facilitates earlier isolation of infected individuals and enables appropriate, cost-effective use of antibiotic therapy. Its current assays include Group B Streptococcus (GBS), methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile toxin B gene (tcdB), and a combination assay for methicillin-resistant Staphylococcus aureus and Staphylococcus aureus (MRSA and SA). Rapid screening can transform patient care and significantly reduce healthcare costs and the emergence of antimicrobial resistant organisms.
